STOCKHOLM, July 26, 2019 /PRNewswire/ --
Second quarter
- Revenue increased by 25.9% to €202.9m (€161.1m). Organic
revenue grew by 14.2%.
- Operating profit amounted to €10.1m (€7.5m), representing an
operating margin of 5.0% (4.7%).
- Net profit amounted to €4.9m (€5.5m), which represents a net
profit margin of 2.4% (3.4%).
- EBITDA increased by 28.8% to €27.3m (€21.2m), corresponding to
an EBITDA margin of 13.5% (13.2%), impacted by €1.6m (€0.2m) merger
and acquisition related costs expensed.
- EBITDAaL increased by 32.6% to €17.5m (€13.2m), corresponding
to an EBITDAaL margin of 8.6% (8.2%).
- Cash flow from operating activities increased to €15.7m
(€14.7m).
- Basic/diluted earnings per share were €0.031 (€0.039).
First half
- Revenue increased by 24.6% to €402.6m (€323.0m). Organic
revenue grew by 14.6%.
- Operating profit amounted to €21.4m (€16.5m), representing an
operating margin of 5.3% (5.1%).
- Net profit amounted to €11.8m (€14.0m), which represents a net
profit margin of 2.9% (4.3%).
- EBITDA increased by 26.3% to €54.8m (€43.4m), corresponding to
an EBITDA margin of 13.6% (13.4%), impacted by €1.8m (€0.5m) merger
and acquisition related costs expensed.
- EBITDAaL increased by 30.0% to €36.0m (€27.7m), corresponding
to an EBITDAaL margin of 8.9% (8.6%).
- Cash flow from operating activities amounted to €39.8m
(€28.4m).
- Basic/diluted earnings per share were €0.077 (€0.099).
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q2
2019
|
Q2
2018
|
Growth
|
6M
2019
|
6M
2018
|
Growth
|
FY
2018
|
|
Revenue
|
202.9
|
161.1
|
26%
|
402.6
|
323.0
|
25%
|
671.6
|
|
Operating
profit
|
10.1
|
7.5
|
35%
|
21.4
|
16.5
|
30%
|
33.7
|
|
Operating profit
margin, %
|
5.0%
|
4.7%
|
|
5.3%
|
5.1%
|
|
5.0%
|
|
Net profit
|
4.9
|
5.5
|
-11%
|
11.8
|
14.0
|
-16%
|
24.2
|
|
Net profit margin,
%
|
2.4%
|
3.4%
|
|
2.9%
|
4.3%
|
|
3.6%
|
|
Basic/diluted
earnings per share, €
|
0.031
|
0.039
|
-21%
|
0.077
|
0.099
|
-22%
|
0.167
|
|
|
|
|
|
|
|
|
|
EBITDA
|
27.3
|
21.2
|
29%
|
54.8
|
43.4
|
26%
|
90.7
|
|
EBITDA margin,
%
|
13.5%
|
13.2%
|
|
13.6%
|
13.4%
|
|
13.5%
|
|
EBITDAaL
|
17.5
|
13.2
|
33%
|
36.0
|
27.7
|
30%
|
58.5
|
|
EBITDAaL margin,
%
|
8.6%
|
8.2%
|
|
8.9%
|
8.6%
|
|
8.7%
|
|
EBITA
|
11.6
|
8.0
|
45%
|
24.1
|
17.6
|
37%
|
37.0
|
|
EBITA margin,
%
|
5.7%
|
5.0%
|
|
6.0%
|
5.4%
|
|
5.5%
|
For definition and reconciliation of alternative performance
measures, refer to note 10.
All comparative figures have been restated for the impact of the
adoption of IFRS 16, Leases compared to the published
consolidated financial statements as at and for the year ended
2018. Refer to the restatement release of 17
April 2019.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CEST) on
26 July 2019. This interim report and
other information about Medicover is available at
medicover.com.
Contact information
For further information, please contact:
Hanna Bjellquist, Head of Investor
Relations
Phone: +46-70-303-32-72
E-mail: hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and
diagnostic services company and was founded in 1995. Medicover
operates a large number of ambulatory clinics, hospitals,
specialty-care facilities and laboratories and the largest markets
are Poland and Germany. In 2018, Medicover had revenue around
€672 million and 20,970 employees. For more information, go to
www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/interim-report-april-june-2019,c2869696
The following files are available for download:
|
https://mb.cision.com/Main/15662/2869696/1082147.pdf
|
Interim report
April-June 2019
|
